Sclerostin is a promising therapeutic target for oral inflammation and regenerative dentistry.
J Transl Med
; 20(1): 221, 2022 05 13.
Article
en En
| MEDLINE
| ID: mdl-35562828
ABSTRACT
Sclerostin is the protein product of the SOST gene and is known for its inhibitory effects on bone formation. The monoclonal antibody against sclerostin has been approved as a novel treatment method for osteoporosis. Oral health is one of the essential aspects of general human health. Hereditary bone dysplasia syndrome caused by sclerostin deficiency is often accompanied by some dental malformations, inspiring the therapeutic exploration of sclerostin in the oral and dental fields. Recent studies have found that sclerostin is expressed in several functional cell types in oral tissues, and the expression level of sclerostin is altered in pathological conditions. Sclerostin not only exerts similar negative outcomes on the formation of alveolar bone and bone-like tissues, including dentin and cementum, but also participates in the development of oral inflammatory diseases such as periodontitis, pulpitis, and peri-implantitis. This review aims to highlight related research progress of sclerostin in oral cavity, propose necessary further research in this field, and discuss its potential as a therapeutic target for dental indications and regenerative dentistry.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Osteogénesis
/
Osteoporosis
Límite:
Humans
Idioma:
En
Revista:
J Transl Med
Año:
2022
Tipo del documento:
Article
País de afiliación:
China